Andrea Russo (Cooper University Health Care, New Jersey, US) discusses the background and rationale behind the BRUISE CONTROL 1 and 2 studies. BRUISE CONTROL 1 looked at patients receiving warfarin and compared randomised patients to uninterrupted anticoagulation with warfarin versus bridging with heparin. BRUISE CONTROL 2 then compared uninterrupted direct oral anticoagulant therapy to holding the drug for at least 24 hours prior to the procedure. The data from the two studies lead to an investigation into other factors that present bleeding risk, including antiplatelet agents. Dr Russo discusses the background and rational of the BRUISE CONTROL 1 and 2 studies, the results of the combined analysis presented at EHRA 2018 and the next steps in this area of research over coming years.
Filmed at EHRA 2018, Barcelona.
View more content here.
1. What was the background and rationale behind the BRUISE CONTROL 1 and 2 studies? 0:09
2. What are your highlights from this year’s meeting? 2:33
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via open-access content in multimedia formats.